Actively Recruiting
Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )
Led by Daihong Liu · Updated on 2026-01-14
168
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for grade II acute GVHD (graft-versus-host disease )
CONDITIONS
Official Title
Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with hematological diseases
- Underwent first allogeneic hematopoietic stem cell transplantation from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies
- Developed new onset of grade II acute GVHD or intermediate/high risk acute GVHD within 100 days post-transplantation based on modified GVHD Glucksberg criteria
You will not qualify if you...
- Recipients of second allogeneic stem cell transplant
- Acute GVHD caused by donor lymphocyte infusion or interferon
- Received first line acute GVHD treatment before enrollment
- Overlap GVHD syndrome
- Pregnant or breast-feeding women
- Serum creatinine greater than 2.0 mg/dL or creatinine clearance less than 40 mL/min
- Uncontrolled infection
- Human immunodeficiency virus infection
- Active hepatitis B or C virus infection requiring antiviral treatment
- Evidence of relapsed primary disease, relapse treatment after transplant, or graft rejection
- Allergic history to Janus kinase inhibitors
- Severe organ dysfunction unrelated to GVHD including unresolved liver veno-occlusive disease, significant cardiac disease (such as recent heart attack, severe heart failure, circulatory collapse, or arrhythmia needing treatment), or severe respiratory disease requiring mechanical ventilation or high oxygen
- Previous Janus kinase inhibitor therapy after transplant for any reason
- Any condition that would interfere with study participation or pose significant risk according to investigator's judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Hematology, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
Research Team
L
Liping Dou, M.D., Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here